MedicarePartD.guide

A non-government resource built from CMS public data

IL-17, IL-23 and IL-12/23 biologics on every 2026 Oklahoma Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 11 stand-alone Part D plans in Oklahoma cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days

11 plans, cheapest premium first. Scroll sideways for all of them →

IL-17, IL-23 and IL-12/23 biologics by 2026 Oklahoma Part D plan
DrugBlue Cross MedicareRx Basic$0.00/moS5715-015Humana Basic Rx Plan$0.00/moS5884-144Wellcare Value Script$5.60/moS4802-156Wellcare Classic$5.70/moS4802-014Humana Value Rx Plan$33.70/moS5884-202HealthSpring Extra Rx$65.40/moS5617-373AARP Medicare Rx Saver from UHC$82.40/moS5921-368Humana Premier Rx Plan$108.60/moS5884-169AARP Medicare Rx Preferred from UHC$121.00/moS5921-404HealthSpring Assurance Rx$126.50/moS5617-113Blue Cross MedicareRx Value$167.30/moS5715-010
StelaraustekinumabNot coveredTier 5PA25%QL 1.5/84dNot coveredNot coveredTier 5PA26%QL 1.5/84dTier 5PA25%QL 0.5/28dNot coveredTier 5PA33%QL 1.5/84dNot coveredTier 5PA25%QL 0.5/28dNot covered
ustekinumab biosimilarsWezlana, Selarsdi, Pyzchiva and othersNot coveredTier 5PA25%QL 1.5/84dNot coveredNot coveredTier 5PA26%QL 1.5/84dTier 5PA25%QL 0.5/28dNot coveredTier 5PA33%QL 1.5/84dNot coveredTier 5PA25%QL 0.5/28dNot covered
Wezlanaustekinumab-auubNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Selarsdiustekinumab-aeknNot coveredNot coveredNot coveredNot coveredNot coveredTier 3PA17%QL 0.5/28dNot coveredNot coveredNot coveredTier 3PA20%QL 0.5/28dNot covered
SkyrizirisankizumabTier 5PA25%QL 6/365dTier 5PA25%QL 2/84dTier 5PA25%QL 6/365dTier 5PA25%QL 6/365dTier 5PA26%QL 2/84dTier 5PA25%QL 2/28dTier 5PA25%QL 1/28dTier 5PA33%QL 2/84dTier 5PA31%QL 1/28dTier 5PA25%QL 2/28dTier 5PA25%QL 6/365d
TremfyaguselkumabTier 5PA25%QL 3/56dTier 5PA25%QL 3/84dTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dTier 5PA26%QL 3/84dTier 5PA25%QL 2/28dTier 5PA25%Tier 5PA33%QL 3/84dTier 5PA31%Tier 5PA25%QL 2/28dTier 5PA25%QL 3/56d
CosentyxsecukinumabTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA25%QL 10/28dTier 5PA25%QL 10/28dTier 5PA26%QL 8/28dTier 5PA25%QL 10/28dTier 5PA25%QL 10/30dTier 5PA33%QL 8/28dTier 5PA31%QL 10/30dTier 5PA25%QL 10/28dTier 5PA25%QL 8/28d
TaltzixekizumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
BimzelxbimekizumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.